Anti-Fibrinolytic Drugs - Ukraine

The projected revenue for the Anti-Fibrinolytic Drugs market in Ukraine is expected to reach US$9.33m by 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 4.96%, leading to a market volume of US$11.89m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, with US$9.86bn expected in 2024.
The demand for anti-fibrinolytic drugs is rising in Ukraine due to the increasing prevalence of bleeding disorders in the country.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Ukraine has been experiencing steady growth in recent years.

Customer preferences: Anti-Fibrinolytic Drugs are primarily used to prevent excessive bleeding during surgery or to treat bleeding disorders. In Ukraine, these drugs are commonly used in surgeries, especially in orthopedics, cardiovascular, and neurosurgery. There is also a growing demand for these drugs in the treatment of inherited bleeding disorders such as hemophilia.

Trends in the market: The Anti-Fibrinolytic Drugs market in Ukraine is expected to continue its growth trajectory in the coming years. This is due to the increasing number of surgeries being performed in the country, as well as the rising prevalence of inherited bleeding disorders. Additionally, there is a growing trend towards the use of anti-fibrinolytic drugs in trauma patients to reduce bleeding.

Local special circumstances: One of the major challenges faced by the Anti-Fibrinolytic Drugs market in Ukraine is the lack of availability of these drugs in many hospitals across the country. This is due to the limited funding available for healthcare in Ukraine, which has resulted in a shortage of medical supplies and equipment. Additionally, the high cost of these drugs has made them unaffordable for many patients.

Underlying macroeconomic factors: The healthcare sector in Ukraine is undergoing significant reforms, which are aimed at improving the quality of care and increasing access to medical services. This is expected to have a positive impact on the Anti-Fibrinolytic Drugs market, as it will result in better funding for healthcare and increased availability of medical supplies. Additionally, the growing economy in Ukraine is expected to result in higher levels of disposable income, which will increase the demand for healthcare services.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.